The estimated Net Worth of R. Erik Holmlin is at least $1.29 Millón dollars as of 16 May 2023. R Holmlin owns over 15,000 units of Bionano Genomics Inc stock worth over $387,108 and over the last 6 years he sold BNGO stock worth over $0. In addition, he makes $898,590 as President, Chief Executive Officer y Director at Bionano Genomics Inc.
Sign up
R Holmlin BNGO stock SEC Form 4 insiders trading
R has made over 2 trades of the Bionano Genomics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of BNGO stock worth $9,600 on 16 May 2023.
The largest trade he's ever made was buying 15,000 units of Bionano Genomics Inc stock on 16 May 2023 worth over $9,600. On average, R trades about 1,669 units every 44 days since 2019. As of 16 May 2023 he still owns at least 806,474 units of Bionano Genomics Inc stock.
You can see the complete history of R Holmlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
R. Erik Holmlin biography
DR. R. Erik Holmlin Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Holmlin has served as our President and Chief Executive Officer and as a member of our board of directors since January 2011. From June 2010 to February 2011, Dr. Holmlin served as president and Chief Executive Officer of GenVault Corporation, a private biosample management solutions company. Previously, Dr. Holmlin held positions as an entrepreneur in residence at Domain Associates, a dedicated life sciences venture capital firm; Chief Commercial Officer of Exiqon A/S, a publicly traded RNA research solutions company; founder and executive at GeneOhm Sciences, which was acquired by Becton Dickinson and Company; and a National Institutes of Health postdoctoral fellow at Harvard University. Until June 2016, Dr. Holmlin served as a director of Nanosphere, Inc., a publicly traded molecular diagnostic company, which was subsequently acquired by Luminex Corporation, a publicly traded biological testing company. Dr. Holmlin received his bachelor’s degree in chemistry from Occidental College, his Ph.D. in chemistry from the California Institute of Technology and MBAs from University of California, Berkeley and Columbia University. Our board of directors believes that Dr. Holmlin’s over 17 years of experience in the life sciences and healthcare industries, which includes the areas of technology development, product commercialization and venture financing, qualifies him to serve on our board of directors.
What is the salary of R Holmlin?
As the President, Chief Executive Officer y Director of Bionano Genomics Inc, the total compensation of R Holmlin at Bionano Genomics Inc is $898,590. There are no executives at Bionano Genomics Inc getting paid more.
How old is R Holmlin?
R Holmlin is 52, he's been the President, Chief Executive Officer y Director of Bionano Genomics Inc since 2011. There are 3 older and 3 younger executives at Bionano Genomics Inc. The oldest executive at Bionano Genomics Inc is David Barker, 78, who is the Independent Chairman of the Board.
What's R Holmlin's mailing address?
R's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.
Insiders trading at Bionano Genomics Inc
Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart y Christopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.
What does Bionano Genomics Inc do?
at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o
What does Bionano Genomics Inc's logo look like?
Complete history of R Holmlin stock trades at Bionano Genomics Inc
Bionano Genomics Inc executives and stock owners
Bionano Genomics Inc executives and other stock owners filed with the SEC include:
-
R. Erik Holmlin,
President, Chief Executive Officer, Director -
Mark Oldakowski,
Chief Operating Officer -
Dr. Robert Erik Holmlin,
Pres, CEO, Sec. & Director -
David Barker,
Independent Chairman of the Board -
Christopher P. Stewart,
Chief Financial Officer -
Kristiina Vuori,
Independent Director -
Christopher Twomey,
Independent Director -
Albert Luderer,
Independent Director -
Hannah Mamuszka,
Director -
Yvonne Linney,
Director -
Alka Chaubey,
Chief Medical Officer -
Christopher Stewart,
Chief Financial Officer -
Dr. Charles Lee Ph.D.,
Scientific Advisor -
Prof. Pui-Yan Kwok,
Scientific Advisor -
Dr. Paul R. Selvin Ph.D.,
Scientific Advisor -
Mark Adamchak,
Controller -
Richard Shippy,
Chief Bus. Officer -
Robert J. Priar,
Chief Commercial Officer -
Dr. Alka Chaubey FACMG, Ph.D.,
Chief Medical Officer -
Aleksandar Rajkovic,
Director -
Robert J Priar,
Chief Commercial Officer -
Michael James Ward,
Former Chief Financial Officer -
Heather Adams,
Chief Administrative Officer -
Warren Robinson,
Chief Commercial Officer -
Darren Cai,
Director -
Quan Zhou,
Director -
Junfeng Wang,
Director -
Soheil Shams,
Chief Informatics Officer -
Richard Shippy,
Chief Business Officer -
Vincent Jung Fai Wong,
Director -
Jonathan V. Dixon,
GENERAL COUNSEL -
Gulsen Kama,
Chief Financial Officer